Johnson & Johnson is expected to ask federal officials this week to authorize a booster dose for the company’s one-shot coronavirus vaccine, according to The New York Times.
The Monday report, which cited “officials familiar with the company’s plans,” said J&J plans to make the request “early this week.”
The news came more than a week after Rochelle Walensky, director of the Centers for Disease Control and Prevention, signed off on allowing booster shots for the Pfizer-BioNTech COVID-19 vaccine for people ages 65 and older, residents of long-term care facilities and vulnerable Americans ages 18 to 64, according to The Associated Press. Her recommendation also included boosters for people who work in health care or other fields with increased risks, as well as those who live in prisons, homeless shelters and other group settings.
The U.S. Food and Drug Administration said last week that its expert advisory committee plans to meet Oct. 14 to discuss possible emergency use authorization of a booster shot of Moderna’s COVID-19 vaccine. The committee will discuss the possibility of a J&J booster the next day, according to the FDA’s website.
In a news release last month, J&J said a Phase 3 study found that a second dose given 56 days after the first shot provided 94% protection against symptomatic COVID-19 in the U.S., 75% protection against symptomatic illness globally and 100% protection against severe or critical illness.
Antibody levels following a second dose administered two months after the first “rose to four to six times higher than observed after the single shot,” the company said in the Sept. 21 release. Meanwhile, a booster administered six months after the first shot prompted a nine-fold increase in antibody levels one week after the second dose, and a 12-fold increase four weeks after the second shot, the release said.
In another study, researchers also found that a single dose of the vaccine “showed strong and long-lasting protection in the real world,” according to the release. Citing data collected from March to late July in the U.S., the company said the single-shot vaccine demonstrated 79% efficacy at preventing COVID-19-related infections and 81% efficacy at preventing hospitalizations.
“There was no evidence of reduced effectiveness over the study duration, including when the delta variant became dominant in the U.S. Sequencing data were not available for analysis,” the release said of the study, which included 390,000 vaccinated people and 1.52 million unvaccinated people.
The company’s studies have not yet been peer-reviewed, The Associated Press reported at the time.
More coronavirus pandemic coverage:
©2021 Cox Media Group